[junkie-button url=”https://infomeddnews.com” style=”grey” size=”medium” type=”round” target=”_blank”] HOME [/junkie-button]
“This funding will help LightIntegra advance its commercialization efforts in the USA, and serves as a positive indication of the company’s shareholder support,” said Bill Dubiel, President and Chief Executive Officer. “The financing allows our company to generate working capital while maintaining its existing ownership structure.”
LightIntegra is a medical devices company that provides diagnostics that aim to reduce blood transfusions in cancer patients and minimize platelet refractoriness. The device, called ThromboLUX, identifies non-activated platelet products which are deemed optimal for this patient type. The company launched commercial sales to the US market in April 2017.